ArticleTherapeutic advances in musculoskeletal disease2021

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis.

Cosimo Bruni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.